Amunix Pharmaceuticals Receives $117M

05 Mar, 2021

Amunix Pharmaceuticals Receives $117M
Photo by Mathieu Stern on Unsplash

– Amunix Pharmaceuticals, a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, has raised $117m Series B financing.
– The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management.

Biotechnology Developer Platform Medical North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: